Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: A nation-wide retrospective study in Austria

Cancer

Volumn 107, Issue 10, 2006, Pages 2408-2416

  Fiegl, Michael ^a,b   Falkner, Andreas ^a   Hopfinger, Georg ^b   Brugger, Stefan ^c   Zabernigg, August ^b   Bauer, Franz ^d   Haslbauer, Ferdinand ^b   Demirtas, Dita ^b   Grossschmidt, Peter ^b   Tatzreiter, Georg ^e   Gastl, Günther ^a   Greil, Richard ^f   Schenk, Thomas ^c   Fridrik, Michael ^g   Zojer, Niklas ^h   Andel, Johannes ⁱ   Mian, Michael ^f   Postner, Gerhard ^j   Thaler, Josef ^k   Denz, Hubert ^l   Walla, Burkhard ^m   Hojas, Sabine ⁿ   Kanatschnig, Werner ^o   more..

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Institute for Creative Media Technologies   (Austria)

^d UNIVERSITY HOSPITAL GRAZ   (Austria)

^e DANUBE HOSPITAL   (Austria)

^f University Hospital Salzburg   (Austria)

^g KEPLER UNIVERSITY HOSPITAL   (Austria)

^h WILHELMINEN HOSPITAL   (Austria)

ⁱ Hospital of Steyr   (Austria)

^j KAISER FRANZ JOSEF HOSPITAL   (Austria)

^k Hospital of Wels   (Austria)

^l Academic Natters Hospital   (Austria)

^m Hospital of Dornbirn   (Austria)

ⁿ Hospital of Fürstenfeld   (Austria)

^o GENERAL HOSPITAL KLAGENFURT   (Austria)

more..

Author keywords

Alemtuzumab; Chronic lymphocytic leukemia; Fludarabine; Monoclonal antibody; Refractory

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE; BENDAMUSTINE; BLEOMYCIN; CISPLATIN; CLADRIBINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; GANCICLOVIR; IFOSFAMIDE; IMMUNOGLOBULIN; NAVELBINE; PROCARBAZINE; RITUXIMAB; STEROID; VALACICLOVIR; VINCRISTINE;

ADULT; AGED; ARTICLE; AUSTRIA; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LEUKEMIA; BASAL CELL CARCINOMA; BLEEDING; CYTOMEGALOVIRUS INFECTION; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; ERYTHROCYTE TRANSFUSION; EVALUATION; FEMALE; FOLLOW UP; GASTROENTERITIS; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; LUNG CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SKIN CANCER; THROMBOCYTOPENIA; THROMBOCYTOPENIC HEMORRHAGE; VIRUS PNEUMONIA; VIRUS REACTIVATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; AUSTRIA; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, B-CELL, CHRONIC; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 33751009390     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22263     Document Type: Article

References (21)

1. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002;43:1755-1762.
2. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:1414-1420.
3. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy. 2001;3:137-143.
4. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;332:323-327.
5. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554-3561.
6. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768-773.
7. Berlex Laboratories. Campath (alemtuzumab) [prescribing information]. Montville: Berlex Laboratories, 2005. Available at:http://wwwberlex.com/html/ products/pi/Campath_PI.pdf [accessed July 2005].
8. Keating M, Coutre S, Rai K, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma. 2004;4:220-227.
9. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
10. Haider I, Cahill M. Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology. 2004;9:409-411.
11. Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003;98:773-778.
12. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997;15:1567-1574.
13. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891-3897.
14. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23:2971-2979.
15. Stilgenbauer S, Krober A, Winkler D, et al. Efficacy of subcutaneous alemtuzumab (Campath-1H) in genetic high-risk, fludarabine-refractory CLL: CLL2H study of the German CLL Study Group (GCLLSG) [abstract 041]. Ann Oncol. 2005;2005: v43.
16. Stilgenbauer S, Winkler D, Krober A, et al. Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL: interim analysis of the CLL2H study of the German CLL Study Group (GCLLSG) [abstract 478]. Blood. 2004;104:140a.
17. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070-4078.
18. Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol. 2005;23:7024-7031.
19. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 2002;99:2245-2247.
20. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278-3281.
21. Rai K, Keating MJ, Coutre S, Rizzieri A. Patients with refractory B-CLL and T-PLL treated with alemtuzumab (Campath) on a compassionate basis. A report on efficacy and safety of CAM511 trial [abstract 3165]. Blood. 2002;100:802a.